clinical trial · NCT06812104
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
Kyowa Kirin Co., Ltd.·phase1·recruiting·n = 156
Relapsed or Refractory AML and Other Hematologic MalignanciesKK2845_1KK2845_2KK2845_3KK2845_4KK2845_5KK2845_6KK2845_7KK2845_8
brief summary
This is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies, in Part 1, the tolerability of KK2845 will be evaluated to determine the maximum tolerated dose (MTD). In Part 2, additional data will be collected by administering KK2845 at dose levels for which tolerability has been confirmed.
started
Oct 10, 2024
primary completion
Nov 30, 2031
completion
Nov 30, 2031
last updated
Jul 1, 2026
official title
A Phase I, Multicenter, Non-controlled, Open-label, Non-randomized, Dose-escalation Study of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol